You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 17, 2025

Claims for Patent: 12,268,664


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 12,268,664
Title:Administration of benzodiazepine compositions
Abstract:The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
Inventor(s):Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio
Assignee: Neurelis Inc
Application Number:US18/782,666
Patent Claims: 1. A pharmaceutical composition for intranasal administration comprising: about 1 to about 20 mg of diazepam dissolved in about 45% to about 85% (w/w) of one or more natural or synthetic tocopherols or tocotrienols selected from the group consisting of: α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, δ-tocotrienol, tocophersolan, any esters thereof and any combinations thereof, and about 25% to about 40% (w/w) of one or more alcohols selected from the group consisting of ethanol, propyl alcohol, butyl alcohol, pentanol, benzyl alcohol, and any combinations thereof, and about 0.01% to about 1% (w/v) of dodecyl β-D-maltoside, wherein the pharmaceutical composition is a solution and contains less than 1% water, wherein the pharmaceutical composition is in a pharmaceutically-acceptable spray formulation.

2. The pharmaceutical composition of claim 1, wherein the one or more natural or synthetic tocopherols or tocotrienols is α-tocopherol.

3. The pharmaceutical composition of claim 1, wherein the therapeutically effective amount of the diazepam is present in the pharmaceutical solution at a concentration of about 10 mg/mL to about 250 mg/mL.

4. The pharmaceutical composition of claim 1, wherein the diazepam is present in the pharmaceutical solution at a concentration of about 20 mg/mL to about 50 mg/mL.

5. The pharmaceutical composition of claim 1, wherein the diazepam is about 2 mg to about 10 mg.

6. The pharmaceutical composition of claim 1, wherein the pharmaceutical solution comprises one or more natural or synthetic tocopherols or tocotrienols, or any combinations thereof in an amount from about 60% to about 75% (w/w).

7. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises at least one additional ingredient selected from the group consisting of stabilizers, coloring agents, pH adjusters, buffering agents, preservatives, wetting agents, flavoring agents and combinations thereof.

8. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is about 25 μL to about 250 μL.

9. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is about 50 μL to about 150 μL.

10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is about 100 μL.

11. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition contains less than 0.5% water.

12. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition contains less than 0.25% water.

13. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition contains less than 0.1% water.

14. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition contains no water.

15. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition contains no more than 0.01% of a diazepam impurity.

16. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition contains no more than 0.01% of a diazepam impurity at 25° C. and 60% relative humidity, 30° C. and 65% relative humidity and 40° C. and 75% relative humidity.

17. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition maintains a similar average spray content at 25° C. and 60% relative humidity, 30° C. and 65% relative humidity and 40° C. and 75% relative humidity each measured at one month, three months and six months.

18. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition maintains a similar average spray content uniformity at 25° C. and 60% relative humidity and 40° C. and 75% relative humidity.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.